Please ensure Javascript is enabled for purposes of website accessibility


Hun Chi Lin, Ph. D.

Dr. HunChi Lin is the CEO of FusionVax, Inc., an early phase R&D company developing DNA vaccine for the treatment of HPV-associated cancers.  He is also the CEO of LionGene Corporation, a company providing health information management service platform company.

He has over 30 peer-reviewed publications and numerous

Dr. Lin created the Clinical Trials Division at Specialty Laboratories.  He has extensive clinical trial experiences including drugs, biologics, and medical devices.  Prior to becoming the Director of Clinical Trials, Dr. Lin managed the largest research operation in the U.S. clinical laboratory industry.  In addition, he supervised and managed over 100 research collaborations with scientists from academic research institutes within the U.S. and abroad.  Prior to joining Specialty Laboratories, he co-developed Trigen, Inc. a company was focused on the treatment and diagnosis of type-1 diabetes.  

He was the Chairman and CEO of Global TransBiotech, Inc. (GTB). GTB applied an asset appreciation business model that focuses on in-licensing post-discovery promising technology and product leads in life science area, developing the technology and product leads to achieve predefined goals and create substantial value, and then out-licensing to pharmaceutical and biotech companies for further development and commercialization. 
in professional conferences and holds 4 patents. 

Dr. Lin was the advisor to Industry Technology Research Institute (ITRI) and Center for Disease Control (CDC) of Taiwan. 

Dr. Lin graduated from UCLA and holds a Ph.D. degree in Microbiology.  He graduated from National Taiwan University and holds a Master degree in Food Science and Technology and a B.S. degree in Agricultural Chemistry.